TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE) filed its financial and operating results today for its fiscal quarter ended June 30, 2014.
Highlights for the quarter include:
- Conducted non-brokered private placements yielding gross proceeds of $1,244,560, which together with financings closed in fiscal Q4 2014, is sufficient to fund Phase I clinical trials for Antibe’s lead drug, ATB-346
- Received approval from Health Canada to begin ATB-346 clinical studies in humans (June 18th)
- Commenced Phase I clinical trial by delivering the first human dose of ATB-346 (June 26th)
The Corporation’s unaudited Q1 2015 financial statements and MD&A have been filed on SEDAR.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID).
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.